The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online
doi:10.1084/jem.20070419
The Journal of Experimental Medicine, Vol. 204, No. 10, 2397-2405
The Rockefeller University Press, 0022-1007 $30.00
© Trotta et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 1964K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trotta, R.
Right arrow Articles by Caligiuri, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trotta, R.
Right arrow Articles by Caligiuri, M. A.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

The PP2A inhibitor SET regulates natural killer cell IFN-{gamma} production

Rossana Trotta1, David Ciarlariello1, Jessica Dal Col1, Jeffrey Allard, II1, Paolo Neviani1, Ramasamy Santhanam1, Hsiaoyin Mao1, Brian Becknell1,2, Jianhua Yu1, Amy K. Ferketich3, Brittany Thomas1, Aalok Modi1, Bradley W. Blaser1,2, Danilo Perrotti1,5, and Michael A. Caligiuri1,4,5

1 Department of Molecular Virology, Immunology and Medical Genetics, 2 Medical Scientific Program, Integrated Biomedical Graduate Program, College of Medicine and Public Health; 3 Division of Epidemiology, College of Public Health; 4 Division of Hematology and Oncology, Department of Internal Medicine; and 5 The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210

CORRESPONDENCE Rossana Trotta: rossana.trotta{at}osumc.edu; OR Michael A. Caligiuri: michael.caligiuri{at}osumc.edu

Monokines (i.e., interleukin [IL]-12, -18, and -15) induce natural killer (NK) cells to produce interferon-{gamma} (IFN-{gamma}), which is a critical factor for immune surveillance of cancer and monocyte clearance of infection. We show that SET, which is a potent inhibitor of protein phosphatase type 2A (PP2A) activity, is highly expressed in human CD56bright NK cells, which produce more IFN-{gamma} than CD56dim NK cells. SET was up-regulated upon monokine stimulation of primary human NK cells. Furthermore, ectopic overexpression of SET significantly enhanced IFN-{gamma} gene expression in monokine-stimulated NK cells. In contrast, RNAi-mediated suppression of SET expression renders NK cells inefficient in producing high levels of IFN-{gamma} in response to monokine costimulation. Mechanistically, suppression of PP2A activity by SET is important for IFN-{gamma} gene expression in NK cells. In fact, treatment of primary human NK cells with the PP2A activator 1,9-dideoxy-forskolin, as well as administration of the drug to C57BL/6 mice, significantly reduced NK-dependent IFN-{gamma} production in response to monokine treatment. Further, SET knockdown or pharmacologic activation of PP2A diminished extracellular signal-regulated kinase 1/2, p65RelA, signal transducer and activator of transduction 4 (STAT4), and STAT5 activity in monokine-stimulated NK cells, potentially contributing to the reduction in IFN-{gamma} gene expression. Thus, SET expression is essential for suppressing PP2A phosphatase activity that would otherwise limit NK cell antitumoral and/or antiinflammatory functions by impairing NK cell production of IFN-{gamma}.


Abbreviations used: APC, allophycocyanin; CTS, cytostatin; ERK, extracellular signal-regulated kinase; I1PP2A, PP2A inhibitor 1; I2PP2A, PP2A inhibitor 2; MAP, mitogen-activated protein; MAPK, MAP kinase; PP2A, protein phosphatase type 2A; shRNA, short hairpin RNA; PP2Ac, PP2A catalytic subunit; STAT, signal transducer and activator of transduction.

M.A. Caligiuri and D. Perrotti contributed equally to this paper.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS